Goldman Sachs’s Rani Therapeutics RANI Stock Holding History

Goldman Sachs’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.93K	Sell	11,740 -86	-0.7%	-$76	﹤0.01%	6483
2026 Q1	$8.69K	Sell	11,826 -274,006	-96%	-$350K	﹤0.01%	6385
2025 Q4	$386K	Buy	+285,832	New	+$431K	﹤0.01%	5754
2023 Q2	–	Sell	-33,532	Closed	-$173K	–	6010
2023 Q1	$173K	Buy	+33,532	New	+$202K	﹤0.01%	5343
2022 Q3	–	Sell	-10,739	Closed	-$111K	–	6490
2022 Q2	$111K	Sell	10,739 -16,081	-60%	-$185K	﹤0.01%	5824
2022 Q1	$362K	Buy	+26,820	New	+$445K	﹤0.01%	5541
2021 Q4	–	Sell	-60,649	Closed	-$1.08M	–	6662
2021 Q3	$1.08M	Buy	+60,649	New	+$1.05M	﹤0.01%	4683

Other funds holding RANI

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs's RANI Position: Q2 2026 in Review

Goldman Sachs reduced its Rani Therapeutics (RANI) stake by 0.73% in Q2 2026, selling an estimated $76 and leaving 11,740 shares worth $8.93K. The position accounts for ﹤0.01% of the portfolio, ranked #6483.

Goldman Sachs first reported a position in RANI in Q3 2021 and has held it in 7 quarters since. The position peaked at $1.08M in Q3 2021. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

Goldman Sachs held 11,740 shares of Rani Therapeutics worth $8.93K as of Q2 2026.
Goldman Sachs sold 86 Rani Therapeutics shares in Q2 2026, an estimated $76.
Rani Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6483 holding.
Goldman Sachs first reported a position in Rani Therapeutics in Q3 2021 and has held it in 7 quarters since.
Goldman Sachs's Rani Therapeutics position peaked at $1.08M in Q3 2021.
68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.